Addendum to "You Will Know Them by Their Fruits"
A timeline of Covid-19 bio-weapon development.
Refer back to the post "You Will Know Them by Their Fruits" for a guide to this timeline.
These are events referenced by Glen Beck, David Martin in their videos. Also included are some interesting patents related to S-spike proteins and mRNA “vaccines”.
Also check out the documents referenced by Glen Beck in his video.
1984: Fauci becomes the boss of NIH. The goal: to use vaccines as the only way to treat ANY human condition.
Nov. 14, 1986: "Childhood Vaccine Injury Act". "NCVIA's purpose was to eliminate the potential financial liability of vaccine manufacturers due to vaccine injury claims[1] to ensure a stable market supply of vaccines, and to provide cost-effective arbitration for vaccine injury claims."
1987: "Canine Coronavirus Vaccine": "A vaccine for protecting a canine animal from disease caused by infection with CCV and from disease caused by infection with one or more additional pathogenic organisms or viruses which comprises an effective amount of the cell-associated peplomer protein and an effective amount of an antigenic component which is protective against such one or more additional pathogenic organisms or viruses". A spike protein herein is called "a peplomer protein". There is the basis for Covid-19 vaccines that use S-spike protein as the antigen to develop antibodies to.
Mar 28, 2001: a patent application US10/655,667 "Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo". The present invention is concerned generally with humoral antibodies specific against epitopes of human immunodeficiency virus (HIV). It is particularly directed to the synthesis and use of gp41 fusion protein constructs as immunogens and vaccines effective for inducing HIV-specific serum IgG and secretory IgA antibodies in vivo.
2002-04-19: Application for a U.S. patent 7279327 "Methods for producing recombinant coronavirus", filed by the University of North Carolina at Chapel Hill, describes methods for producing recombinant coronaviruses (https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/virus-recombinant). Ralph Baric, Ph.D., a professor of microbiology and immunology who is famous for his chimeric coronavirus research, is listed as one of the three inventors, along with Kristopher Curtis and Boyd Yount. According to Martin, Fauci, Baric and the CDC “are at the hub” of the whole COVID-19 story. This is a patent for “an infectious, replication defective, coronavirus particle, that specifically targets lung epithelial cells wherein said cell is a coronavirus permissive cell...” This virus was genetically modified to infect humans more effectively! The research and development of this research was funded by Dr. Anthony Fauci from the NIH! There were claims that this research was initiated to develop HIV vaccines using coronaviruses as vectors. However, the research deployed genetically modifying platforms to enhance the coronavirus to infect human cells using the ACE2 receptors.
Oct. 2002 - Feb. 21, 2003: Severe acute respiratory syndrome (SARS) was a new human disease in the autumn of 2002. It first occurred in Southern China in November 2002 and was transported to Hong Kong on February 21, 2003 by an infected and ill patient. Ten secondary cases spread the infection to two hospitals in Hong Kong and to Singapore, Toronto and Hanoi. In March 2003 a novel coronavirus (SARS-CoV) was found to be the causative agent. (https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106085/) .
Apr. 24, 2003: CDC files a patent on SARS virus U.S. Patent. 7,776,521 "Coronavirus isolated from humans". The CDC actually owns the entire genetic content of that SARS virus. The patent covered the isolated virus that causes SARS and ways to detect it. They also own patents for detection methods, and for a kit to measure the virus. The key take-home message Martin delivers in “Plandemic” is that there’s a distinct problem with the CDC’s patent on SARS-CoV isolated from humans, because, by law, naturally occurring DNA segments are prohibited from being patented.
Jul. 2003: Ralph Baric successfully created "an infectious clone of the urbani strain of the SARS coronavirus" (https://web.archive.org/web/20210819100926/http://www.xinhuanet.com/english/2021-08/19/c_1310136639.htm). "Army's top bio-level three labs in Maryland," according to an article published by UNC-Chapel Hill in 2003 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC240733/).
June 2005: DARPA gets in on the game Synthetic Coronaviruses. "Biohacking: Biological Warfare Enabling Technologies", Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Oct. 25, 2005: R. S. Baric, A. C. Sims "Development of mouse hepatitis virus and SARS-CoV infectious cDNA constructs”
Oct. 2005: A Bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. (https://www.congress.gov/109/bills/s1821/BILLS-109s1821is.pdf). The money starts being openly channeled from the US budget to the development of "influenza vaccines".
2006: “DEPARTMENT OF DEFENSE, EMERGENCY SUPPLEMENTAL APPROPRIATIONS TO ADDRESS HURRICANES IN THE GULF OF MEXICO, AND PANDEMIC INFLUENZA ACT, 2006” adopts "Rule of Construction Concerning National Vaccine Injury Compensation Program" TARGETED LIABILITY PROTECTIONS FOR PANDEMIC AND EPIDEMIC PRODUCTS AND SECURITY COUNTERMEASURES; "releases qualified pandemic or epidemic product" "authorized for emergency use in accordance with section 564 of the Federal Food, Drug, and Cosmetic Act".
Feb. 2007: Ralph Baric "A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice" - a gain-of-function research making SARS more lethal. "We adapted the SARS-CoV (Urbani strain) by serial passage in the respiratory tract of young BALB/c mice. Fifteen passages resulted in a virus (MA15) that is lethal for mice following intranasal inoculation. ... The availability of the MA15 virus will enhance the use of the mouse model for SARS because infection with MA15 causes morbidity, mortality, and pulmonary pathology. This virus will be of value as a stringent challenge in evaluation of the efficacy of vaccines and antivirals."
Sep. 2012: The MERS outbreak. Health officials first reported the disease in Saudi Arabia in September 2012. Through retrospective (backward-looking) investigations, they later identified that the first known cases of MERS occurred in Jordan in April 2012. So far, all cases of MERS have been linked through travel to, or residence in, countries in and near the Arabian Peninsula. The largest known outbreak of MERS outside the Arabian Peninsula occurred in the Republic of Korea in 2015. The outbreak was associated with a traveler returning from the Arabian Peninsula.
2013: 6 Mojiang miners were infected with atypical pneumonia:"Some patients (1, 2, and 4) showed clotting complications such as pulmonary thromboembolism or thrombosis and elevated D-dimer values. Dr. Zhong Nanshan, a doctor for respiratory diseases and a national advisor for the SARS and COVID-19 epidemic, had provided remote consultation for patients 3 and 4, the most serious patients. Patients 3 and 4 remained in the hospital for more than 100 days. Four patients (1–4) a very low oxygenation index and classified as ARDS (Berlin criteria, 2012). Dr. Nanshan's diagnosis for patients 3 and 4 were interstitial pneumonia (primarily of viral origin), with a possibility of secondary infection (invasive pulmonary aspergillosis)."
2013: DARPA started funding Moderna mRNA (https://www.keionline.org/33832). Also see https://f.hubspotusercontent10.net/hubfs/8079569/The%20FauciCOVID-19%20Dossier.pdf
Mar. 13, 2013: "Prefusion RSV F proteins and their use" “Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed.”
Sep. 4, 2014: Patent Application US16/557,894 "Recombinant hiv-1 envelope proteins and their use": “HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject.”
2014: Just before a ban on gain-of-function research went into effect in the US, Shi Zhengli, a top Chinese virologist, a.k.a. the bat lady (https://en.wikipedia.org/wiki/SHC014-CoV), did work with researchers from Ralph Baric’s laboratory in North Carolina, where gain-of-function research on bat coronaviruses was carried out, and published a paper "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797993/): “Using the SARS-CoV reverse genetics system (the CDC-patented SARS virus sequence), we generated and characterized a chimeric virus expressing the spike of bat coronavirus SHC014 in a mouse-adapted SARS-CoV backbone. The results indicate that group 2b viruses encoding the SHC014 spike in a wild-type backbone can efficiently use multiple orthologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-CoV. Additionally, in vivo experiments demonstrate replication of the chimeric virus in mouse lung with notable pathogenesis.”
2015-04-27: "Nucleoside-Modified RNA For Inducing an Adaptive Immune Response" Application filed by The Trustees Of The University Of Pennsylvania, Acuitas Therapeutics inc. The Canadian company Acuitas Therapeutics is behind a core component of the Pfizer and BioNTech COVID-19 vaccine development. “...mRNA vaccine development has been hampered due to problems with mRNA stability, delivery and immunogenicity directed against the mRNA itself via the innate immune system. While optimization of RNA vaccines has proven somewhat effective in recent years in an ex vivo setting, current methods of producing mRNA vaccines provide poor antibody and CD8+ T-cell responses when directly administered in vivo. ...In one embodiment, the composition further comprises a lipid nanoparticle (LNP). In one embodiment, the at least one nucleoside-modified RNA is encapsulated within the LNP. “
2015-11-09: the cooperation in developing mRNA vaccines starts between NIH and Moderna with "Confidential Disclosure Agreement 2015-33448" (https://www.citizen.org/article/the-nih-vaccine/#_ftn2) “The Confidential Information disclosed under this Agreement is described as: For NIAID: NIAID's proprietary information and data relating to the development of vaccines for HIV, influenza, Ebola and MERS and development of broadly neutralizing monoclonal antibodies for preventative and therapeutic use. For Collaborator: Moderna's proprietary and confidential information related to design and manufacture of a messenger RNA platform and messenger RNA constructs for treatment and prevention of disease.”
2015: Peter Daszak calls for pan-influenza or pan-coronavirus vaccine (SARS declared eradicated by WHO in 2008 https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/severe-acute-respiratory-syndrome).
Nov. 9, 2015: Baric, Zhengli-Li "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence" : “Having established that the SHC014 spike has the ability to mediate infection of human cells and cause disease in mice, we next synthesized a full-length SHC014-CoV infectious clone based on the approach used for SARS-CoV (Fig. 3a)2. Replication in Vero cells revealed no deficit for SHC014-CoV relative to that for SARS-CoV (Fig. 3b); however, SHC014-CoV was significantly (P < 0.01) attenuated in primary HAE cultures at both 24 and 48 h after infection (Fig. 3c). In vivo infection of mice demonstrated no significant weight loss but showed reduced viral replication in lungs of full-length SHC014-CoV infection, as compared to SARS-CoV Urbani (Fig. 3d,e). Together, the results establish the viability of full-length SHC014-CoV, but suggest that further adaptation is required for its replication to be equivalent to that of epidemic SARS-CoV in human respiratory cells and in mice.
Chimeric and full-length viruses were confirmed by sequence analysis before use in these studies. Synthetic construction of chimeric mutant and full-length SHC014-CoV was approved by the University of North Carolina Institutional Biosafety Committee and the Dual Use Research of Concern committee.”
2016-10-25: U.S. Application No. 16/344,774 " Prefusion Coronavirus Spike Proteins and Their Use" (Priority to US201662412703, US patent US10960070B2 granted 2021-03-31) ”Federal scientists in partnership with academic researchers developed a new way to stabilize coronavirus spike proteins. The approach required substituting two amino acids, known as prolines, between the central helix and heptad repeat 1 (“the 2P approach”). The stabilized spike protein for an earlier coronavirus produced a stronger immune response at lower doses than the naturally occurring protein.”
2016-10-26: "Lipid nanoparticle mRNA vaccine": “The present invention relates to lipid nanoparticles comprising mRNA and to medical uses thereof. The lipid nanoparticles of the present invention include an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein, as well as cationic lipids according to formulas I, II or III and/or PEG lipids according to formula IV. In addition, the present invention relates to the use of such lipid nanoparticles as a vaccine or medicament, in particular in connection with vaccination against influenza or rabies.”
2016-10-27: "Nucleoside-modified rna for inducing an adaptive immune response"
2018-05-17: “Collaborative research and licensing opportunity: Prefusion coronavirus spike proteins and their use”: “Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection.
CoV spike (S) proteins mediate cellular attachment and membrane fusion and are therefore the target of protective antibodies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection. This technology is applicable for delivery via other platforms, such as mRNA.”
Jan. 2019: many NIH vaccine patents related to the coronavirus vaccine were allowed to lapse, except NIH forced UNC Chapel Hill to sign the patent for S1 spike protein patent back to NIH (transferred the rights to the real bioweapon to NIH). CDC's patent on coronavirus that they’ve gotten in Apr. 25, 2003 was allowed to lapse in 2018 (they failed to pay the maintenance fee).
May 2019: NIH and Moderna entered into a “research collaboration agreement” to develop vaccine candidates against Middle East Respiratory Syndrome coronavirus (MERS-CoV) and Nipah virus.
Sep. 18, 2019: “A World at Risk” document from WHO: “3. PREPARING FOR THE WORST: A RAPIDLY SPREADING, LETHAL RESPIRATORY PATHOGEN PANDEMIC”. “Progress indicator(s) by September 2020 • Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.” “Ultimate objectives: The tools and systems needed to respond effectively to a fast-moving and lethal respiratory pathogen are in place: A universal influenza vaccine is effective and routinely used to protect the global population; new therapeutics and broad-spectrum antivirals are widely available to treat and reduce mortality from a range of viruses; novel pathogens are routinely identified and sequenced, and the sequences are shared on a globally accessible website. Distributed manufacturing of vaccines (including nucleic acid types) begins within days of obtaining the new sequences and effective vaccines are pre-tested and approved for use within weeks.”
Sep. 19, 2019: https://www.federalregister.gov/documents/2019/09/24/2019-20804/modernizing-influenza-vaccines-in-the-united-states-to-promote-national-security-and-public-health: “In recognition of these limitations, the President signed the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health on Sep, 19, 2019. Broadly, the Executive Order directs BARDA, CDC, NIH, and FDA to accelerate the adoption of improved influenza vaccine technologies. In alignment with the goals of the Executive Order, NIAID is conducting and supporting research to develop state-of-the-art vaccine platform technologies that could be used to develop universal influenza vaccines as well as to improve the speed and agility of the influenza vaccine development process. These platform technologies include DNA, messenger RNA (mRNA), virus-like particles, vector-based and self-assembling nanoparticle vaccines. For example, NIAID supported scientists are investigating an mRNA vaccine candidate that would allow for a more rapid and flexible response to both seasonal and pandemic influenza than do existing vaccine production strategies.”
Oct. 2019 "Event 201": The event was hosted by the Johns Hopkins Center for Health Security in partnership with the Bill & Melinda Gates Foundation and World Economic Forum. The exercise brought together stakeholders from various sectors, including business and government, to simulate a “severe pandemic” involving a fictional coronavirus, with an outbreak beginning in Brazil.
Dec. 4, 2019: Fauci's Testimony "The Role of the National Institutes of Health in Research Addressing Seasonal and Pandemic Influenza" "The constantly changing nature of seasonal influenza viruses and the threat of the emergence of a pandemic influenza necessitate the development of broadly reactive or “universal” influenza vaccines that could protect individuals over many years against multiple types of influenza viruses, both seasonal and pandemic."
Dec. 12, 2019: Material Transfer agreement "of the mRNA Coronavirus vaccine candidates developed and jointly-owned by NIAID and Moderna to The University of North Carolina at Chapel Hill" for "Perform challenge studies with the mRNA vaccine in a <proprietary info: mammalian?> model as described on Exhibit A". Signed by Ralph Baric.
Dec. 30, 2019: the Wuhan Municipal Health Commission (WHC) issued two emergency notices for internal circulation to local hospitals alerting them to patients with unexplained pneumonia—several of whom worked at Huanan Market—and laying out a treatment and response plan (https://www.science.org/doi/10.1126/science.abm4454).
Jun. 11, 2020: NIH scientists have filed for a provisional U.S. patent application no. 62/972,886 entitled "2019-nCoV vaccine" according to disclosures in a " SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness": ”A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273 - https://www.raybiotech.com/covid19-proteins/?gclid=Cj0KCQiAhf2MBhDNARIsAKXU5GTd2DaBOM4QtgHORFyVp5ucliPWE2q-8x1uMl31wwq8aSJct9_npAAaAmzVEALw_wcB).”